Gastrointestinal Stromal Tumor (GIST)

**Adult trials (Ages 18 and older)**
- All Mutation Types (KIT, PDGFRA D842V, Wild)
  - 2nd Line Only
  - 3rd or 4th Line
    - IRB #19262: A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib (INTRIGUE)
    - IRB #20580: Expanded Access Program for Ripretinib in Patients with Locally Advanced Unresectable or Metastatic GIST Who Have Received Treatment with Prior Therapies
    - IRB #17155: A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy, and Pharmacokinetics in Patients with Advanced Malignancies

**Interventional trials**
- KIT and PDGFRA (D842V) Mutations
  - At least 1 prior therapy
    - IRB #31229: Phase 1, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Subjects with Advanced Gastrointestinal Stromal Tumor

**PDGFRA D842V Only**
- 2nd or 3rd Line
  - IRB #21884: An Open-Label, Phase 2 Efficacy Study of Temozolomide in Advanced SDH Mutant/Deficient GIST

**SDH-Mutant/deficient GIST**
- Adult and Pediatrics

**CROSS-DISEASE TRIALS:**
- IRB# 19992 EAY131 (MATCH)
- IRB# 18084 S1609 (DART)

http://www.ohsu.edu/research/rda/so/knight.php

28DEC2020